Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3068 - Left ventricular ejection fraction(LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Breast Cancer

Presenters

Ja Hyun Yeo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

J.H. Yeo1, H. Ahn2, I. Park2, Y.S. Kim2, S.J. Sym2, E.K. Cho1, D.B. Shin2

Author affiliations

  • 1 Internal Medicine, Gachon Univeristy Gil Medical Center, 21565 - Incheon/KR
  • 2 Medical Oncology, Gachon University Gil Medical Center, 405-760 - Incheon/KR
More

Resources

Abstract 3068

Background

Current guidelines recommend cardiac function monitoring every 3 months in patients receiving trastuzumab, however evidences for optimal cardiac surveillance strategy are lacking. The aim of this study is to identify risk factors and to characterize clinical patterns of trastuzumab related cardiac dysfunction(TRCD) within 1 year of treatment in patients with breast cancer.

Methods

We identified and reviewed consecutive patients with breast cancer received trastuzumab and adequate cardiac monitoring (baseline and subsequent cardiac echocardiogram at least every 4 months) between Jan 2010 - Apr 2017 at a single center. TRCD were defined as an absolte decrease of ejection fraction(EF) ≥15% or ≥ 10% to below the lower limit of normal.

Results

Among 364 patients(median age 51 years), TRCD was developed in 33 patients (9.3%). Median time from trastuzumab to TRCD was 6.3 months(range 2.6-12.3). Incidence of TRCD was significantly higher in patients with prior anthracycline (12.1% vs. 5.1%, p = 0.026). In 20 out of 33 patients (60.6%), TRCD was diagnosed within the first 6 months of trastuzumab. Earlier TRCD was significantly associated with prior anthracycline (72% vs. 25%, p = 0.035). Among the patients with later TRCD development after 9 months of trastuzumab (n = 13), absolute EF decrease >5% in the first 6 months preceded in 10 patients (76.9%). Incidence of later TRCD was significantly lower in patients whose absolute EF decrease < =5% in the first 6 months (2.1%) than in whom with more than 5% of absolute EF decrease (11.8%).

Conclusions

TRCD development occurs earlier within the first 6 months of trastuzumab in patients with prior anthracycline use. The degree of absolute EF decrease in the first 6 months can predict later development of TRCD. Therefore, cardiac monitoring for the first 6 months of trastuzumab treatment should not be missed, especially in whom with prior exposure to anthracyclie. Adaptive less frequent cardiac surveillance strategy after 6 months may be considered in patients without significant EF change.

Clinical trial identification

Legal entity responsible for the study

Hee Kyung Ahn.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.